02 8011 4217, 0416 974 651  info at scenar.com.au

Influence of SCENAR-therapy on the pregnancy course, labor, state of a neonate and a first-year child in women with miscarriage of infectious genesis

Publication: Russian reporter of Gynaecologists and Obstetricians 2, 2009
Authors: L.V. Borovkova, A.A. Artifeksova, S.O. Kolobova
Nizhny Novgorod State Medical Academy
Obstetrics and Gynecology Department
Head of the Department – L.V. Borovkova, Professor

Influence of SCENAR-therapy on the pregnancy course, labor, state of a neonate and a first-year child in women with miscarriage of infectious genesis

Abstract: We investigated effectiveness of SCENAR-therapy in complex treatment of 60 pregnant women with urogenital infections at 16–18 weeks of pregnancy. The control group included 50 pregnant women with similar urogenital infections that underwent conventional antibacterial and antiviral therapy after 16–18 weeks of pregnancy. Using SCENAR-therapy in treating pregnant women with miscarriage of infectious genesis significantly improves prognosis of bearing a child, the state of a fetus, neonate and a first-year child, decreased the incidence and severity of placental inflammatory processes and intrauterine infection.

Miscarriage is not only current medical concern, but also a serious social-economic problem with the case rate 15-20% among all desirable pregnancies. Today urogenital infection is one of the major causes of miscarriage, which may have harmful effect on the course of the pregnancy, state of a fetus and a neonate. Infectious pathology is mainly caused by genital microplasmas, clamydia, herpes simplex virus (HSV) and cytomegalovirus (CMV) [5, 7, 12].

New conditions for infection development are created during gestation. It is connected with general and local immunity peculiarities of pregnant women. Systemic gestational immunosuppression (suppression of inflammatory TH-1-immune response route) in healthy women provides formation of immune tolerance to semiallogenic fetus and pregnancy bearing. During development of acute urogenital infection or reactivation of chronic urogenital infection the T-helpers in the pregnant body significantly decrease and that activates local and general cytotoxic immune, as well as causes depression of humoral Th-2-immune response route. Infectious agents cause hypersynthesis of antiflammatory cytotoxicants (TNF, interleukin-1) providing prothrombinase overproduction, activation of coagulation mechanisms, trombosis in trophoblast vessels, destruction of vascular endothelial and trophoblast damage, as well as production of antiphospholipid and anti-DNA antibodies and formation of specific cytotoxic immune response directed against fetus antigens. Hyper amount of Th-1-route cytoxines increases the production of prostaglandin in amnion and decidua and may cause abortion [7, 11, 12, 14, 15].

It is proved that even massive virus and bacterial infections may not influence the course of pregnancy and fetus development in case a pregnant woman has no evident changes in the immunity. So, negative effect any infection has on a fetus and a neonate mainly depends on the intensity and character of immune status changes of a pregnant woman [12].

Infectious agents may cause certain complications in the course of the pregnancy: abortion (31.7-67.5%), early gestosis (32.4%), gestosis (23.7-49%), pyelonephritis (7-21.4%), anemia (92%), production of autoimmune antibodies (19-51.1%), fetoplacental insufficiency progression (47.6-73.3%), and preterm labor (8.8-16%). Women with urogenital infections may have the following complications during the childbirth: preterm amniorrhea (27.7-39%), pathological preliminary period (6.6-7.1%), labor anomaly (7.1-38.5%). In all types of infection afterbirth period is complicated by subtle late-onset (5-7 days after labor) endometritis (8.4-21.4%) with relapses and uterus subinvolution (13.5%) [5, 12].

It is known that placenta and embryonic membranes protect the fetus from bacteria and viruses. In most cases infectious process just affects placenta and starts the development of adaptative reactions in it (increase in villi vascularization, formation of syncytial node, villi proliferation with increase in placenta volume and mass). At this a newborn can be healthy with good physical and functional parameters. If the effect of infectious activator is too long or repeated, placental porosity excoriates causing the development of placental insufficiency and infectious process in the fetus. Literature says that when bacterial and virus infection inflammatory changes in placenta occur in 11-78.4% cases, placental insufficiency – 50-60%., intrauterine infection develops in 6-53% cases. High incidence rate of fetus infection was observed when inflammation of placenta fetus part and umbilical cord are combined, as well as in virus-virus or virus-bacterial associations. 36.8% of neonates born of women with placental infectious changes have infectious diseases, 25% – hypoxic syndrome and increase of the adaptation period, 55.7% – late cord remain rejection [8, 11, 12, 16, 17, 19].

Intrauterine infection by micoplasmas is observed in 35%, by ureaplasmas – 45%, manifestations of micoureaplasmic fetus infection are aspiration syndrome, interstitial pneumonia, cardiopathy. The most common infections among neonates are: meningitis, encephalitis, skin necrosis, conjunctivitis, pneumonia, osteomyelitis, hemorrhagic syndrome. Intrauterine infection by clamydia is observed in 9.7-63.3% and manifests in a generalized form (affection of eyes, kidneys, skin, lymph nodes), meningoencephalitis, gastroenteropathy, intrauterine pneumonia, conjunctivitis and vulvovaginitis in girls. Intrauterine infection in cytomegalovirus is observed in 0.2-40%, in herpetic infection – 0.01-75%. In most cases fetus infection is connected with primary virus infection during pregnancy. The fetus may be infected transplacental or while passing through the infected maternal passages. In cytomegalovirus the neonate can get infection through the infected breast milk. In cytomegalovirus the fetus has hydrocephaly, hydronephrosis, cystic changes in organs and tissues, as well as hepatitis, nephritis, encephalitis, myocarditis; neonates have the neonatal disease developing (low-birth-weight, jaundice, hepatosplenomegaly, pneumonia, meningoencephalitis, chorioretinitis, interstitial nephritis), developmental defects (microcephaly, paraventricular cyst, biliary atresia, multicystic kidneys, heart failure), late complications (deafness, blindness, encephalopathy, pneumosclerosis, cirrhosis, bowel and kidneys affection, etc). Herpes infection mainly affects the central nervous system, skin and mucous of a fetus, generalized form is also possible; congenital syndrome is observed in neonate (microcephaly, chorioretinitis, intracranial calcification) [5, 6, 9, 10, 12, 13].

If a fetus is infected but there are no manifestations of intrauterine infection, a neonate will have CNS (75-84%), CVS and GIT (26%) dysfunctions. Such children have high risk of developing infectious and allergic diseases, as well as psychomotor retardation during the first year of their life [12].

Modern complex antibacterial and immunocorrective therapy for pregnant women with urogenital infections doesn’t protect from intrauterine infection of the fetus, development of fetoplacental insufficiency, trombophilic complications, labor anomaly, as well as doesn’t improve perinatal outcomes. These are the reasons why doctors still search for new therapies for treating miscarriage of infectious genesis. In different publications we can find discussions on how urogenital infections influence the course of pregnancy and there are contrary points of view on whether pregnant women with urogenital infections should undergo immunocorrection or not. That is why we found it logical to study the effect of infections on the course of the pregnancy, labor, state of a neonate and 1-year child after pregnant women underwent traditional treatment, as well as complex therapy including SCENAR-therapy.

SCENAR is used for therapeutic non-invasive electropulse stimulation of the skin in different pathologies. Pulse bipolar alternate current is used as a stimulating signal sent as pulses with the frequency 10-350Hz including swinging frequency mode (30-120Hz) and can be combined into bursts (2-8 pulses) with repetition rate 540Hz-4.5kHz [18].

Previous researches of Nizhny Novgorod State Medical Academy [1-3] show that SCENAR-therapy has immunomodulatory and anti-inflammatory effect produced due to the decrease of anti-inflammatory citoxin levels. It also normalizes coagulate blood properties due to the decrease of thrombocyte ADP-aggregation and fibrinogen content, as well as antibody levels to cardiolipins, chronic gonadotropin and DNA.

The experiment with white mongrel rats showed that SCENAR short-pulse signals lack embriotoxic and teratogenic properties [4], and that allows to use SCENAR-therapy for treating pregnant women.

Using SCENAR-therapy for treating pregnant women is allowed upon authorization of local ethic committee under State Health Care Institution Nizniy Novgorod Regional Clinical Hospital named after N.A. Semashko. All the women gave a written consent for undergoing SCENAR-therapy.

Research aim was to compare the course of pregnancy, labor process, the state of a neonate and a first-year child of women with miscarriage of infectious genesis while treating urogenital infections with traditional therapies, as well as complex therapy including SCENAR-treatment.

Materials and methods

110 women with urogenital infections composed a control group. All the women were examined, observed clinically during pregnancy, as well as during the childbirth. We also examined the state of the fetus and a neonate.

All the patients were examined at 10-12, 22-24, 36-38 weeks of pregnancy for any manifestations of urogenital infections (clamidiosis, mycoplasmosis, ureaplasmosis, cytomegalovirus and herpetic infections). To diagnose micoplasmosis and ureaplasmosis we used bacteriological test – inoculation of cervical canal. To find clamidiosis, cytomegalovirus and herpetic infections we examined separate cervical canal using the method of polymerase chain reaction (PCR) and blood serum for antibodies (immunoglobulin class A, M, G) to the abovementioned infections using enzyme immunoassay.

In the postnatal period we studied morphological picture of 30 placentas, all the neonates underwent saliva and tear PCR-diagnostics, as well as cord blood EIA to find urogenital infections. First-year children were followed up by neuropathologist.

All the women we observed had urogenital infections as monoinfections (34.5%) or bacterial-virus associations (65.5%). Patients were divided into 2 groups considering their age, social status, past gynecological and extragenital diseases. Patients from the control group (50 women) underwent traditional antibacterial and antivirus therapy after 16-18 weeks of pregnancy. While patients from the main group (60 women) after 16-18 weeks of pregnancy underwent complex therapy with SCENAR-stimulation for 10 days according to the common method, including stimulation of cervical area, vertebral und paravertebral lines, 6 points, liver projection area.

The results were processed using application package for static Excel data processing and accurate difference between the indices was estimated according to the Student’s test. Difference between the compared values were considered as accurate when p<0.05.

Research results and discussion

When comparing clinical picture of the pregnancy we got accurate difference between the indices in main and control groups. So, in control group threatening miscarriage in the I and II pregnancy stages and threatened premature labor were registered in 26%, fetoplacental insufficiency – 20%, arrested fetus prenatal development of the I stage – 8%, dysfunction of utero-placental blood flow of the I stage – 10%. While in the main group miscarriage and fetoplacental insufficiency reduced twice. Acute infections (mainly micoplasmic-herpic and chlamidial-micoplasmic-cytomegalovirus) were observed in 31 (62%) women from the control group, where 10 (20%) had recurrent infection at 36-38 weeks, and in main group process reactivation was observed only in 11 (18.3%) cases and only at 20-24 weeks of pregnancy.

Accurate difference between the indices of the control groups was also manifested while analyzing the labor process. In the control group 44 (88%) women had spontaneous labor, 39 (78%) had labor in time, 5 (10%) – premature labor, 6 (12%) – cesarean section at 38-40 weeks. In the main group 55 (91.7%) women had labor in time and 5 (8.3%) – cesarean section at 38-40 weeks. In the control group 80% had xerotocia, compared to 60% in the main group, primary uterine inertia was observed in 30% and 20%, oxytocia – in 10% and 6.7% respectively. No complications observed in the afterbirth period in both groups. Clinical picture complications of the pregnancy and labor in women with miscarriage of infectious genesis are shown in the table.

The results presented in the table show that complications in the course of pregnancy and labor in women with miscarriage of infectious genesis in both (main and control) groups were observed mainly in the mixed bacterial-virus infection. Estimating the labor outcome for the fetus and the course of neonatal period we found out that in the control group neonates weighted 3206.6±154.7g, while in the main group the weight was 3280.6±176.4g. 5 neonates from the control group (10%) were born premature, 34 (68%) were born with a satisfactory state (8-10 Apgar scores), 9 (18%) – with light asphyxia neonatorum, 7 (14%) – with moderate asphyxia neonatorum and I degree hypertrophy, 16 (32%) – with adaptation disorders in the early neonatal period. In the main group the state of the neonates was much better: the state of 52 (86.7%) was estimated as 8-10 Apgar scores and only 8 (13.3%) had light asphyxia neonatorum and signs of adaptation disorders in the early neonatal period.

Complications in the course of pregnancy and labor Control group Main group
monoinfections bacterial-virus associations monoinfections bacterial-virus associations
Threatened miscarriage 3 10 2 5
Intrauterine growth retardation 0 4 0 0
Dysfunction of utero-placental blood flow of the I stage 0 5 0 0
Placenta premature ripening 0 4 0 4
Oligoamnios 0 2 0 3
Hydramnios 0 2 1 1
Preterm amniorrhea 13 27 10 26
Uterine inertia 5 10 3 9
Oxytocia 0 5 0 4
Preterm labor 0 5 0 0

Table. Complications in the course of pregnancy and labor in women with miscarriage of infectious genesis

Examination of placenta showed some peculiarities in its morphological structure, which depend on the type of urogenital infection and its therapies. Placenta histodiagnosis in the women from the main group showed no inflammatory changes in 9 (60%) cases (women with isolated micoplasmic or ureaplasmic, micoplasmic-ureoplasmic, chlamydial, chlamydial-herpic, micoplasmic-herpic infection). Only in 4 (26.7%) placentas (in chlamydial-cytomegaloviral, chlamydial-micoplasmic infection) we found out few small inflammation focuses in fetal membranes that localized within compact layer and cytotrophoblast, not reaching amniotic epithelium, and in basal membrane. In 2 (13.3%) cases (in women with chlamydial-cytomegaloviral, chlamydial-micoplasmic-cytomegaloviral infection) we manifested single small inflammatory infiltrates in fetal membranes including amniotic epithelium layer and subchorial space and in basal membrane.

Unfortunately only 2 (13.3%) patients (treated for ureaplasmos) from the control group had no inflammatory processes. 1 (6.7%) patient had single small inflammatory focuses in fetal membranes without any damages of amniotic epithelium and in basal membrane (observed after treating isolated micoplasmic infection). 2 (13.3%) patients had changes as small inflammatory infiltrates in fetal membranes, subchorial space and basal membrane. Most often these changes were observed after treating micoplasmic (ureaplasmic) infection. Examination of 10 (66.7%) placentas showed extensive inflammatory changes of the basal membrane, villi, intervillous lacuna, fetal membranes and subchorial space. 7 (46.7%) women out of them (mainly with chlamidial, herpic, chlamidial-herpic infections) had signs of relative compensated chronic placental insufficiency (according to the morphological diagnosis criteria of Tsinzerling and co-authors, 1998) with ill-defined focal involutive-dystrophic processes (focal dystrophic changes in syncytiotrophoblast, fibrinoid accumulation in intervillous lacuna) and well-marked adaptive reactions (hyperplasia and hypervascularization of terminal villi, enlargement of cyncytial nodes and syncytiocapillary membranes). In 3 (20%) women (with chlamydial-cytomegaloviral, chlamydial-micoplasmic-cytomegaloviral, chlamydial-micoplasmic infection) we observed signs of relative subcompensated chronic placental insufficiency with focal disorders in villi maturation (presence of embryonal, mature and immarure intervilli), diffusive fibrinoid accumulation, focal bleeding in intervillous space and active adaptive processes. So, in the main group inflammatory changes in the placentas developed after treating mixed bacterial-viral associations, had focal character and were observed 2.2 times less frequently compared to the control group, where inflammatory processes were well-marked, extensive and developed after treating both isolated and mixed infections. Moreover, the results showed that the most evident and well-marked changes in both groups were observed in mixed bacterial-virus infections.

Diagnosing bacterial and virus infections of the neonates showed that 34 (68%) in the control group) and 52 (86.7%) in the main group) children born in women both with isolated and mixed bacterial-virus infections had no bacterial and virus agents in their saliva and tear. Their blood serum contained specific IgG antibodies against infectious agents in the titer equal or twice smaller than the titer of corresponding mother antibodies. Literature says that signs not fetal infection, but placental antibody transmission [12, 20]. No specific IgM registered.

Analyzing the research results we found out that 16 (32%) neonates from the control group probably had fetal infection: in 9 (8%) neonates born in women that had acute chlamydial-cytomegaloviral, chlamydial-micoplasmic, micoplasmic-herpic infection at 20-24 week of pregnancy, IgG titer against chlamidiae, cytomegalovirus and hepric virus was twice higher than level of mother antibodies (that can sign fetal infection). No IgM found. Examining saliva and tear showed no bacterial and virus agents. Blood serum of 7 (14%) neonates, born in women that had reactivation of chlamydial-micoplasmic, chlamydial-micoplasmic-cytomegaloviral infections at 20-34 weeks and 36-38 weeks of pregnancy, contained high levels of specific IgM antibodies against chlamidiae and cytomegalovirus, titer of IgG against the infections mentioned was 2-4 times higher than the titer of mother antibodies. Examining saliva and tear showed no bacterial and virus agents.

In the main group signs of fetal infection were observed only in 8 (13.3%) neonates born in women that had acute chlamydial-micoplasmic-cytomegaloviral, micoplasmic-herpetic infection at 20-24 weeks of pregnancy. The titer of IgG antibodies against cytomegalovirus and simple herpes in these neonates was twice higher than the level of mother antibodies (that can sign fetal infection). IgG antibodies against chlamidiae was twice lower than titer of mother antibodies. No IgM found. Examining saliva and tear showed no bacterial and virus agents.

Observing the neuropsychic state of the 1-year child we found out that 34 (68%) children from the control group had normal psychomotor development. At this 16 (32%) neonates with light or moderate asphyxia born of women with chlamydial-micoplasmic-cytomegaloviral, micoplasmic-herpetic, chlamydial-micoplasmic, chlamydial-cytomegaloviral infections, extensive inflammatory changes of the fetus with signs of placental inefficiency, were observed at neurologist on perinatal encephalopathy and hypertension jitteriness (10, or 20% cases) and with psychomotor and preverbal retardation (6 or 12% cases). After they underwent treatment manifestations of perinatal encephalopathy by the end of the 1-year disappeared in 9 (8%) and remained in 7 (14%) children, whose mothers suffered from chlamydial-micoplasmic, chlamydial-micoplasmic-cytomegaloviral infections and had extensive inflammatory processes in placenta with signs of subcompensated placental inefficiency. In the main group 52 (86.7%) children had no neuropsychic disorders and only 8 (13.3%) neonates with light asphyxia born of women with chlamydial-micoplasmic-cytomegaloviral, micoplasmic-herpetic infections with ill-defined inflammatory changes of the placenta as focal chorioamnionitis and basal deciduitis had suffered from perinatal encephalopathy and hypertension jitteriness, treating which helped to relieve the symptoms and remove them by the end of the 1 year. So, in the main group the development of perinatal encephalopathy in 1-year children in mixed bacterial-virus infection of the mother was observed 2.4 times less frequently than in the control group. Moreover, in the main group by the end of the first year this pathology had been almost cured (compared to the control group).

Conclusions
1. Most often threatened miscarriage, development of fetoplacental insufficiency, labor anomaly, afterbirth pathology, intrauterine infection, neuropsychological abnormalities in the 1-year children were observed in patients with mixed bacterial-virus associations (compared to monoinfections).

2. SCENAR-therapy in pregnant women with miscarriage of infectious genesis significantly contributed to decrease the case rate and severity level of inflammatory processes in the placenta (from 86.7% cases with well-marked changes in the control group to 40% with ill-defined signs of infection in the main group).

3. SCENAR-therapy in treating pregnant women with miscarriage of infectious genesis significantly improves the prognosis of bearing a child, the state of a fetus, neonate, and first-year child, decreased the incidence of intrauterine infection neuropsychological abnormalities in the 1-year children.

References:

1. L. V. Borovkova. Reproductive function of patients with genital endometriosis: abstract of a thesis. M 2004; 51
2. L.V. Borovkova, I. E. Kholmogorova, V. D. Uchaikina and co-authors. Scientific substantiation of pulse therapy effectiveness for treating infertility in patients with external endometriosis. Reflexology 2005; 3: 58-60

Effect of Artrofoon and SCENAR Therapy on Parameters of LPO and Antioxidant System of the Blood in Patients with Peritonitis in Postoperative Period

Effect of Artrofoon and SCENAR Therapy on Parameters of LPO and Antioxidant System of the Blood in Patients with Peritonitis in Postoperative Period

A. V. Tarakanov, S. Kh. Luspikayan,
N. P. Milyutina, and A. V. Rozhkov

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 136-139, September, 2009
Original article submitted August 1, 2008

Administration of artrofoon in combination with SCENAR therapy to patients with localized suppurative peritonitis in the postoperative period considerably reduced plasma MDA level, stabilized ceruloplasmin activity, and increased catalase activity in erythrocytes compared to the corresponding parameters in patients receiving standard treatment in combination with SCENAR therapy.

Key Words: suppurative appendicular peritonitis; artrofoon; self-controllable energoneuroadaptive regulator (SCENAR); lipid peroxidation; antioxidant enzymes

DOWNLOAD

Electric Device For Bisphosphonate-Induced Osteonecrosis

Abstracts of the 2008 International MASCC/ISOO Symposium

Support Care Cancer (2008) 16:619–756  DOI 10.1007/s00520-008-0457-6

02-026
Electric Device For Bisphosphonate-Induced Osteonecrosis
Boris Zaidiner1, Ilia Baranovsky2, Darya Leontyeva3, Irene Petrenko2 1Regional Cancer Hospital, Out-patient Care, Rostov-on-Don, Russia, 2Medical Unit, Laboratory of Immunology, Rostov-on-Don, Russia, 3Research Cancer Center, Laboratory of Biophysics, Rostov-on-Don, Russia, 4Medical Unit, Laboratory of Endocrinology, Rostov-on-Don, Russia

Objectives: Osteonecrosis of the jaw (ONJ) is serious adverse event in patients (pts) who administer bisphosphonates for metastatic bone disease. Its management outcome remains poor. To improve results of conventional treatment we’ve used electric therapy device (“SCENAR”, US Patent N 5257623) which was tested in some fields of supportive care. This is attempt to show our experience in SCENAR-technology usage for ONJ.

Methods: In preliminary trial 28 pts with bisphosphonaterelated
ONJ (mean age 59,2 years, range 36–81 years) were enrolled; nosologic forms: breast cancer 9 pts, prostate cancer 7 pts, lung cancer 6 pts, multiple myeloma 3 pts, renal cell cancer 2 pts, far-advanced malignancy without verified primary site – 1 patient. Clinical picture was presented with pain (at rest & jaw movement), swelling, exposed bone; suppuration was noted in 3 pts. Dental surgery prior to bisphosphonate therapy was in almost all pts. After signing the informed consent every patient 15 SCENAR-procedures was performed in addition to conventional supportive care. During these procedures various cutaneous and mucosal areas were treated, their choice was based upon patient’s complaints, their technique was described earlier.

Results: In 17 pts (60,7%) positive results were achieved. They felt better, had partial pain relief (the relief ratings on VAS were significantly improved). In 5 of 19 pts with exposed oral maxillofacial bone the lesions had tendency to heal; in 2 of these 5 pts radiographic changes have become less obvious.

Conclusions: In our study group adding SCENAR to standard therapy appeared to result in more promising outcome then available literature data were presented. Further research is necessary to establish its exact position in multimodal approach for bisphosphonate-related ONJ.

 

DOWNLOAD

SCENAR IN ARTERIAL HYPERTENSION

SCENAR IN ARTERIAL HYPERTENSION

N.G. Sivirinova, A.V. Tarakanov, L.V. Klimova
Rostov State Medical University, Rostov-on-Don

All around the world, and in Russia particularly, arterial hypertension is one of the most important and current medical and social problem. It is the key risk factor for most cardio-vascular diseases, myocardial infarctions and strokes that greatly contribute to high mortality in the country. Hypertension affects about 40% of adults.

Sleep is one of the factors that influences the BP level and regulates activity of our body. However, we have lack of scientific data on how sleep influences on hypertension. Today sleep disorders can be treated by medicines, as well as by non-drug therapies. Electric pulse stimulation with SCENAR is one of the non-drug modalities for those who suffer from sleep disorders.

Research objective was to study the effect of SCENAR-therapy on blood pressure parameters and make a subjective assessment of sleep in patients with hypertension.

We gave questionnaire on sleep disorders to hospital patients and on its basis selected 60 patients to participate in the research. Using random sampling, we have divided the patients into 2 groups:

Group 1 – 30 patients (18 men and 12 women), mean age 58.2±1.2 years. This group was control group.

Group 2 – 30 patients (17 men and 13 women), mean age 54.1±1.4 years. This group received complementary therapy with SCENAR.

On examination patients had the following values:

Group 1: systolic blood pressure (SBP) – 1792±20 mmHg, diastolic blood pressure (DBP) – 91.0±1.4 mmHg, heart rate (HR) – 90.0±1.0 bpm.

Group 2: systolic BP – 178.0±2.3 mmHg, diastolic BP – 88.0±2.2 mmHg, heart rate (HR) – 83.9±2.2 bpm.

In both groups patients received common hypertensive medicines, and in Group 2 common therapy was complemented with SCENAR-stimulation (twice a day for two weeks). SCENAR-therapy included stimulation of the collar zone with spaced electrodes using the CHANS-SCENAR-02 device following specific pattern and stimulation in the projection of patient’s complaint with the built-in device electrode. All the patients refused form taking any drugs for treating sleep disorders 2-3 months before the research. The effectiveness of antihypertensive therapy and SCENAR-treatment was assessed by comparing sleep and BP parameters at the end of the hospital treatment. We also evaluated the results of BP Holter monitoring.

Results. By the end of the second week of the treatment we marked that clinical symptoms of arterial hypertension decreased or disappeared, and main hemodynamic parameters changed significantly. The analysis of treatment with SCENAR and without showed that patients from Group 1 and 2 manifest the decrease of SBP by 24.3 and 24.5%, DBP by 10.3 and 13,1 %, HR by 17.3 and 16.0%, double production by 37.3 and 36.0% respectively. Comparative analysis showed no significant difference in the abovementioned BP parameters in patients who received SCENAR-treatment. However, it not enough to use only integral BP parameters to evaluate the effectiveness of SCENAR as all the mechanisms of the hemodynamic adaptive response are not investigated enough.

We have analyzed the subjective assessment of sleep and identified that appropriate antihypertensive therapy in Group 1 has almost no effect on characteristics of sleep. Total score changed from 18.3 to 19.4 points. While including SCENAR into the treatment contributes to significant and positive changes in pre-, intra- and postsomnia processes, faster falling asleep and longer duration of sleep, fewer night wake-ups, better quality of sleep, less nightmares, and better quality of morning wake-ups. Total score changed from 11 to 24 points. That signs that patients cured the insomnia associated with the hypertension. However, we can’t state for sure whether sleep disorders are primary or secondary when accompanied with arterial hypertension.

Analysis of Holter monitoring showed different results of SCENAR-therapy. We marked that average pulse pressure in Group 1 and 2 decreased by 17.8 and
41.5%, daily index of SBP significantly decreased by 26.3 and 52.4%, daily index of DBP by 34.2 and 40.8% respectively. The nighttime effect was very positive: in Group 1 and 2 average SBP decreased by 21.3 and 30.7% (P<0,05), average DBP by 18.1 and 21.1%, SBP variability decreased by 28.2 and 58.0% (P<0,05), DBP variability decreased by 14 and 32.2% (P<0,05) respectively.

Findings. We have identified that patients after SCENAR manifest normalization and stabilization of blood pressure, if compared with the control group, improved pressure parameters according to Holter monitoring, as well as improved sleep parameters. The associated pathology didn’t get worse. SCENAR is very effective and safe complementary treatment modality, therefore it could be considered as non-drug therapy that could be recommended for hypertonic patients with sleep disorders.

Using SCENAR-therapy for treating hypertension crisis in pre-hospital period

Published in: Reflexology – 2008 – No. 3-4 – pp. 23-26

Authors: Los E.G., Tarakanov A.V., Hatisova E.V., Department of Emergency Medical Aid at the State University – Rostov-on-Don

Title: Using SCENAR-therapy for treating hypertension crisis in pre-hospital period

Key words: SCENAR-therapy, hypertension crises, pre-hospital period

Annotation: The article shows the effectiveness and safety of SCENAR-therapy when used for uncomplicated hypertension crises in pre-hospital period (n=97), with gradual reliable cardiac rate fall, decrease of the parameters of arterial tension, and decreased frequency of complaints in 20 minutes after the manipulation. The effectiveness of SCENAR-therapy gives evidence of human body’s existing powerful self-regulatory abilities to repair its damaged functions, and the use of this method is an alternative treatment for some cases in this category of patients.

 

DOWNLOAD

 

The use of electronic biofeedback for the management of post-herpetic neuralgia-a report of 3 cases.

 2007 Sep;66(9):232, 234.

The use of electronic biofeedback for the management of post-herpetic neuralgia–a report of 3 cases.

Abstract

The purpose of these case reports is to describe treatment of three consecutive patients with post-herpetic neuralgia using a bioelectronical device (SCENAR). The instrument is approved as a Class II device in the United States. The electrode of the device was stroked gently over the involved skin area for up to 15 minutes per session. No more than 5 sessions over a 3-week period was required. All patients experienced substantial relief of pain from the first treatment. One patient required only 1 treatment lasting 10 minutes. The other 2 patients required 4 to 5 treatments over a 3-week period. One patient required a treatment for skin itch after one year with a follow up period of 6 months to 24 months. An electronic biofeedback device (SCENAR) may be successfully utilized in the management of post-herpetic neuralgia.

Effect of arthrophon with use of Transcutaneous Neurostimulation on values of lipid peroxidation at complex post-surgical therapy in patients with purulent appendicular peritonitis

Effect of arthrophon with use of Transcutaneous Neurostimulation on values of lipid peroxidation at complex post-surgical therapy in patients with purulent appendicular peritonitis

Publication: Pharmacology – Practical Healthcare, Issue No: 7, September 2007, St. Pertersburg, Russia

Authors: Luspikayan S.H., Tarakanov A.V., Voronkin D.A.)
State medical university of Rostov, 29, Nahichevan st., Rostov-on-Don, 344022

The tumour necrosis factor-alpha (TNF) plays a significant part in inflammatory destruction of pathogenesis.

Purpose – to explore the influence of arthrophon in respect of its bipathic effect combined with transcutaneous neurostimulation (SCENAR-therapy) on the state of lipid peroxidation, values of endogenous intoxication at treatment of patients with purulent appendicular peritonitis in post-surgical period.

Materials and methods: 58 patients were examined who were operated for purulent peritonitis. All the patients were treated with conventional intensive therapy. In group 1 (n =38) treatment combined with SCENAR was performed. In group 2 (n=20), four tablets per day of arthrophon were additionally prescribed, plus 5 procedures of SCENAR-therapy. The control (n=36) – healthy donors comparable as age and sex. Evaluation of efficiency was performed according to clinical and laboratory data on the first and fifth day from the start of the treatment. Application of arthrophon led to decrease of the level of myeloperoxidase with 50.1% (p<0.001). The activity of catalase increased with 41% compared with the initial background (p<0.02) and reached the control group. In both groups, statistically reliable decrease of malondialdehyde (MDA) was noted as well as decrease of diene-conjugates on the 5th day of the treatment. The level of intoxication was defined according to the fraction of medium-mass molecules in blood plasma. After a five-day course of therapy in the first group the contents of medium-mass molecules (280) decreased with 28.8% (p<0.01), in the second group – with 39% (p<0.001). In the second group, decrease of medium-mass molecules was noted – 30.3% (p<0.05), in the first group a reliable change of this value was not noted. On the background of arthrophon and SCENAR-therapy, the level of circulating immune complex dramatically decreases 5 days after the treatment – 40.3% (p<0.01).

Conclusions: arthrophon combined with SCENAR-therapy proves to be an effective therapeutic means for post-surgical period in patients with purulent appendicular peritonitis. A significant decrease of clinical symptoms of the disease was noted, as well as normalization of paraclinical values. The combined therapy allows to correct faster and more efficiently the extent of endogenous intoxication, which were evaluated with reliable decrease of some fractions of medium-mass molecules and circulating immune complex. Arthrophon and SCENAR-therapy combined with basic intensive therapy in post-surgical period in patients with purulent appendicular peritonitis decreased the intensity of processes of lipid peroxidation on the 5th day, increased anti-oxidant protection and improve the function condition of cellular membranes.

SCENAR-technology for chemotherapy-induced neurotoxicity

Abstracts of the 20th Anniversary International MASCC/ISOO Symposium

Support Care Cancer (2007) 15:651–797 DOI 10.1007/s00520-007-0262-7

P-153
SCENAR-technology for chemotherapy-induced neurotoxicity
B. Zaidiner1, N. Lyan2, I. Baranovsky3, I. Petrenko4 1Regional Cancer Hospital, Department of Ambulatory Care, Rostov-on-Don, Russia 2Medical Unit BIOCAR, Rostov-on-Don 3Medical Unit “Zdorov’e”, Rostov-on-Don 4Pharmacy Unit, Rostov-on-Don

Background: Drug toxicity is the major limiting factor in chemotherapy (CT) of malignancies. Anti-cancer agents produced a broad range of side effects that diminish patients’ quality of life and limit their ability to tolerate the pIanned treatment regimen. The supportive care for these patients is routinely based on chemoprotectants: mesna, amifostine etc., the physical factors in this context are less common.

Our previous works have shown the efficacy of SCENARdevice (US Patent 1 5257623) for pain relief and some other issues. We’ve tried to present our experience in usage of SCENAR-technology for CT-induced neurotoxicity.

Materials and methods: In this preliminary trial 36 pts (mean age 46.8±7.6 years) with advanced ovarian cancers were observed. All patients were treated with Pt derivatives (oxaliplatin, cisplatin), whose cumulative dose have being ?540 mg/m*; they suffered from burning & aching pains and paresthesias; sensory deficit was noted. After signing the informed consent every patient 15 SCENAR-procedures were done in addition to conventional supportive therapy. These procedures consisted of treatment of various cutaneous areas which were chosen as applied patient’s complaints. They were conducted daily, their technique was described earlier.

Results: We’ve achieved positive results in 23 patients (63.9%) who felt better, their pain relief ratings on Visual Analogue Scale were significantly improving, part of them could refuse or reduce analgesic usage), the sensory disturbances were partially restored. The reasonable results were noted in 8 (22.2%) and bad in 5 (13.9%) patients. The analgesic reducing helped to prevent their side-effects.

Conclusion: SCENAR may be useful for patients with  anticancer toxicity as a part of comprehensive therapeutic program. Its exact position in variety of clinical situations will be established in the randomized placebo-controlled trial which is being conducted now. We conceive our results to be promising for continued study of SCENAR technology in supportive care.

 

DOWNLOAD

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

INBOHAN,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

RYOONGHUH,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

ABSTRACT

SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. We investigated the usefulness and effectiveness of SCENAR therapy in patients with MPS. SCENAR therapy was performed in 202 patients with MPS. The ratio of male to female was 1:4.5. The mean age was 47.3 years (range: 18-75 years). The mean follow up period was 6 months (range: 3 months-16months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy. The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory. This study suggests that SCENAR therapy would be very useful new method to deal with MPS.

INTRODUCTION

Myofascial pain syndrome (MPS) is a local or regional musculoskeletal pain disorder that may involve either a single muscle or a muscle group. It develops due to any number of causes including sudden trauma to musculoskeletal tissues. It seems to occur in virtually everyone’s lives at some point but becomes chronic and intractable in some cases. MPS has a significant impact on functional status, restricting occupational activities with marked socioeconomic repercussions. The management of MPS encompasses a range of different interventions, including trigger point injections, drug, exercise, patient education, physiotherapy, and alternative therapies. The treatment goals are to relieve pain, reduce muscle spasm, improve strength and range of motion, promote early return to activity, encourage active coping strategies, and ultimately improve functional status. The risks and benefits of these treatments vary. SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid 80s. We experienced the clinical benefit provided by SCENAR therapy and demonstrated the effectiveness of SCENAR therapy.

ISBN: 978-81-904262-8-2(RPS) ©2007 WACBE’07. All rights reserved.

METHODS

The study population was composed of 202 patients with MPS. The ratio of male to female was 1: 4.5. The mean age was 47.3 years (range: 18-75 years). SCENAR therapy was performed between August 2005 and December 2006. The mean frequency of this treatment was 3 times a week and the mean duration time per each treatment was 5 minutes. The mean follow up period was 6 months (range: 3 months- 16 months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy.

RESULTS

The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory.

DISCUSSIONS

SCENAR was first invented in Russia in mid 80s under space and military research program. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. SCENAR therapy is contraindicated in patients with cardiac pacemakers due to the potential of interfering with pacemaker activity.
SCENAR therapy can be differentiated from TENS. They use electrical stimulation. However, the pulse of the SCENAR device is bipolar and has short triangle and high amplitude. The electrodes of SCENAR device were fixed. Our study suggests that SCENAR therapy would be very useful method to deal with MPS.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pam in electrical nerve stimulation. Clinical
Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657-266

Proa of the 3rd WACBE World Congress on Bioengineering 2007

 

SCENAR THERAPY FOR LYMPHEDEMA

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR LYMPHEDEMA

R YOONG HUH, MD
Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu,Sungnam, 463-712, Korea
INBOHAN, MD Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu, SUngnam, 463-712, Korea

ABSTRACT
SCENAR standing for Self-Controlled Energo Neuro-Adaptive Regulator was first invented in mid 80s. The goal of therapy for Jymphedema is lymphatic drainage. We investigated the usefulness and effectiveness of SCENAR therapy in patients with lymphadema. SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in-7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment -was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment. The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, – SCENAR therapy would be very useful method to deal with lymphedema.

ISBN: 978-8l-904262-8-2(RPS) ©2007 WACBE’07. Ail rights reserved.

INTRODUCTION

Lymphedema is a debilitating progressive condition with no known cure. The underlying problem is lymphatic dysfunction, resulting in an abnormal accumulation of interstitial fluid containing hig h molecular weight proteins. It is usually observed following breast cancer surgery, particularly among those who undergo radiation therapy following axiallary lymphadenectomy. In a disease state, the lymphatic transport capacity is reduced. This causes the normal volume of interstitial fluid for mation to r\exceed the rate of lymphatic return, resulting in the stagnation of high molecular weigh t proteins in the interstitium. Surgical treatment is palliative, not curative, and it does not obviate the need for continued medical therapy.

SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid SOs. We experienced the clinical benefit provided by SCENAR therapy for patients with lymphedema and demonstrated the effectiveness of SCENAR therapy.

METHODS

SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in 7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment.

RESULTS
The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients.

DISCUSSIONS
Lymphedema is a notoriously debilitating progressive condition caused by damage or removal of regional lymph nodes through surgery, radiation, infection, or tumor invasion. The goal of therapy is lymphatic drainage. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body.
Although the pathophysiology of lymphedema is still unclear, it has been reported that protein and fluid accumulation initiates a marked inflammatory reaction in the interstitium. Macrophage activity is increased, resulting in destruction of elastic fibers and production of fibrosclerotic tissue.
The result of this inflammatory reaction is a change from the initial edema to the brawny nonpitting edema characteristics of lymphedema. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, SCENAR therapy would be very useful method to deal with lymphedema.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pain in electrical nerve stimulation. Clinical Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657- 266

Proc. of the 3rd WACBE World Congress on Bioengineering 2007